Alentis Therapeutics AG
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alentis.ch
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- Conditions
- Squamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 170
- Registration Number
- NCT06747585
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸NEXT Oncology Virginia, Fairfax, Virginia, United States
Study of ALE.C04 in Patients With Head and Neck Cancer
- Conditions
- Head and Neck CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT06054477
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of Southern California USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Yale University Yale Cancer Center, New Haven, Connecticut, United States
Rescue of Nephrons With ALE.F02 (RENAL-F02)
- Conditions
- Glomerulonephritis Rapidly Progressive
- Interventions
- Drug: PlaceboDrug: Immunosuppressive Agents
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 80
- Registration Number
- NCT06047171
- Locations
- 🇩🇪
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany
🇩🇪Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Germany
🇪🇸Hospital Regional Universitario de Malaga, Malaga, Spain
A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
- Conditions
- Advanced Liver FibrosisLiver Cirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Alentis Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT05939947
- Locations
- 🇺🇸
American Research Corporation, San Antonio, Texas, United States
🇩🇪APEX GmbH, Munich, Germany
🇷🇴ARENSIA Exploratory Medicine S.R.L., Bucharest, Romania